Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC). A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC

NCT00509457 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT00509457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC). A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC
Lead sponsor
Oslo University Hospital
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2006
Completion date
August 31, 2009
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung